Anticancer innovative therapy congress: Highlights from the 10th anniversary edition.

De Santis F

De Santis F(1), Fucà G(1), Schadendorf D(2), Mantovani A(3), Magnani L(4), Lisanti M(5), Pettitt S(6), Bellone M(7), Del Sal G(8), Minucci S(9), Eggermont A(10), Bruzzi P(11), Bicciato S(12), Conte P(13), Noberini R(9), Hiscott J(14), De Braud F(15), Del Vecchio M(1), Di Nicola M(16).
Author information:
(1)Immunotherapy and Innovative Therapeutics Unit, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
(2)Department of Dermatology, University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany.
(3)Istituto Clinico Humanitas IRCCS, Rozzano, Italy.
(4)Department of Surgery and Cancer, Imperial College London, London, UK.
(5)Translational Medicine, School of Science, Engineering and Environment [SEE], Biomedical Research Centre [BRC], University of Salford, Greater Manchester, United Kingdom.
(6)The CRUK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom.
(7)Cellular Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, I.R.C.C.S. Ospedale San Raffaele, Milan, Italy.
(8)Department of Life Sciences, University of Trieste, 34127, Trieste, Italy.
(9)Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
(10)Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands.
(11)Unit of Clinical Epidemiology, Ospedale Policlinico San Martino - IRCCS, Genoa, Italy.
(12)Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.
(13)Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
(14)Laboratorio Pasteur, Istituto Pasteur-Fondazione Cenci-Bolognetti, 00161, Rome, Italy.
(15)Department of Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
(16)Immunotherapy and Innovative Therapeutics Unit, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: [Email]

https://dx.doi.org/10.1016/j.cytogfr.2021.02.001

During the Tenth Edition of the Annual Congress on "Anticancer Innovative Therapy" [Milan, 23/24 January 2020], experts in the fields of immuno-oncology, epigenetics, tumor cell signaling, and cancer metabolism shared their latest knowledge on the roles of i] epigenetics, and in particular, chromatin modifiers, ii] cancer metabolism, iii] cancer stem cells [CSCs], iv] tumor cell signaling, and iv] the immune system. The novel therapeutic approaches presented included epigenetic drugs, cell cycle inhibitors combined with ICB, antibiotics and other off-label drugs, small-molecules active against CSCs, liposome-delivered miRNAs, tumor-specific CAR-T cells, and T-cell-based immunotherapy. Moreover, important evidence on possible mechanisms of resistance to these innovative therapies were also discussed, in particular with respect to resistance to ICB. Overall, this conference provided scientists and clinicians with a broad overview of future challenges and hopes to improve cancer treatment reasonably in the medium-short term.